Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.
Siddhee A SahasrabudheMarcia R TerlukKyle D RudserJames C CloydReena V KarthaPublished in: International journal of molecular sciences (2022)
The lack of reliable biomarkers is a significant challenge impeding progress in orphan drug development. For appropriate interpretation of intervention-based results or for evaluating candidate biomarkers, other things being equal, lower variability in biomarker measurement would be helpful. However, variability in rare disease biomarkers is often poorly understood. Type 1 Gaucher disease (GD1) is one such rare lysosomal storage disorder. Oxidative stress and inflammation have been linked to the pathophysiology of GD1 and validated measures of these processes can provide predictive value for treatment success or disease progression. This study was undertaken to investigate and compare the extent of longitudinal biological variation over a three-month period for various blood-based oxidative stress and inflammation markers in participants with GD1 on stable standard-of-care therapy (N = 13), treatment-naïve participants with GD1 (N = 5), and in age- and gender-matched healthy volunteers (N = 18). We utilized Bland-Altman plots for visual comparison of the biological variability among the three measurements. We also report group-wise means and the percentage of coefficient of variation (%CV) for 15 biomarkers. Qualitatively, we show specific markers (IL-1Ra, IL-8, and MIP-1b) to be consistently altered in GD1, irrespective of therapy status, highlighting the need for adjunctive therapies that can target and modulate these biomarkers. This information can help guide the selection of candidate biomarkers for future intervention-based studies in GD1 patients.
Keyphrases
- oxidative stress
- randomized controlled trial
- dna damage
- end stage renal disease
- replacement therapy
- healthcare
- palliative care
- stem cells
- diabetic rats
- ischemia reperfusion injury
- chronic kidney disease
- systemic lupus erythematosus
- computed tomography
- peritoneal dialysis
- cell therapy
- cross sectional
- signaling pathway
- chronic pain
- health insurance
- heat shock
- disease activity
- affordable care act